Last updated on June 2020

A Study of Ibrutinib in Combination With Rituximab in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)


Brief description of study

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment nave or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).

Clinical Study Identifier: NCT04062448

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.